PHQ-9
Articles tagged with “PHQ-9”
What Side Effect Data Tells Us About Ketamine Dosing
New analysis of NMDA receptor antagonist side effects in treatment-resistant depression underscores why dose optimization and early monitoring matter.
Ketamine Side Effects & When to Switch: New Clinical Guidance
New clinical guidance urges tracking PHQ-9 scores, monitoring side effects closely, and switching NMDA treatments sooner to reach remission faster.
NMDA Antagonist Side Effects: What the Data Now Shows
Psychiatric Times reviews side effect profiles and dropout rates for NMDA antagonists like ketamine. Here's what it means for low-dose ketamine patients.
Tracking Treatment Response to Ketamine: PHQ-9, MADRS, and Clinical Scales
A clinician's guide to systematic outcome measurement in ketamine therapy, covering validated rating scales, assessment frequency, response and remission thresholds, and data-driven decision-making for dosing adjustments.
Measuring Ketamine Treatment Outcomes: Validated Assessment Tools
Review of validated assessment tools for measuring ketamine treatment outcomes, covering depression rating scales, suicidality measures, functional assessments, and biomarkers.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.